- Market Capitalization, $K 12,273,412
- Shares Outstanding, K 95,409
- Annual Sales, $ 48,960 K
- Annual Income, $ -268,910 K
- 60-Month Beta 1.11
- Price/Sales 246.31
- Price/Cash Flow N/A
- Price/Book 8.26
|Period||Period Low||Period High||Performance|
| || |
-11.65 (-8.30%)since 08/17/21
| || |
-32.45 (-20.14%)since 06/17/21
| || |
+47.81 (+59.15%)since 09/17/20
The COVID-19 pandemic has accelerated the pace of the global healthcare market’s growth. With the widespread adoption of digital technologies and increased healthcare spending, the industry is expected...
/PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and...
Schrodinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), an innovative...
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, UNH, ZLAB, PEP, and PFE.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZLAB, NVAX, JNJ, MARA, and RIOT.
Even though NIO (NIO) has delivered spectacular returns over the past year, Tencent (TME), Bilibili (BILI), and Zai Lab (ZLAB) have outperformed the stock so far this year. Based on growing market demand...
The biotechnology sector has been the focus of investors since the outbreak of the COVID-19 pandemic. Initially, all eyes were on accurate COVID-19 testing, followed by an anxious wait for vaccines. The...
Bilibili Inc.’s (BILI) entertainment platform enables its users to consume and create content. The company has quickly become quite popular as its user base has increased exponentially due to the coronavirus....
, /PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The issue price is per share; the stock opens...
, /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today that it had closed a Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital,...
|Zai Lab Ltd ADR|
|Global X MSCI China Health Care ETF|
|Global X China Biotech Innovation ETF|
|Etfmg Treatments Testing and Advancements ETF|
|Bioshares Biotech Products|
|Invesco Nasdaq Biotechnology ETF|
|3rd Resistance Point||139.67|
|2nd Resistance Point||134.88|
|1st Resistance Point||131.76|
|1st Support Level||123.85|
|2nd Support Level||119.06|
|3rd Support Level||115.94|